11 September 2019
(Journal 6799) GB1910899.2 Applicant: Scancell Limited
Title: Binding members
Date Lodged: 31 July 2019
11 September 2019
(Journal 6799) GB1910900.8 Applicant: Scancell Limited
Title: Modified fc-regions to enhance functional affinity of antibodies and antigen binding fragments thereof
Date Lodged: 31 July 2019
16 October 2019
(Journal 6804) GB1912657.2 Applicant: Scancell Limited
Title: Binding members
Date Lodged: 3 September 2019
Yeah probably to do with Avidimab.... the quiet building of that all valuable IP
Their NASDAQ listing BioNTech have themselves a snazzy new website
can't find a mention of scancell but notice their collab with Lilly has reached a preclinical end
'T Cell Receptor Cell Platform
We are developing T cell receptor therapies for the treatment of cancer, including in collaboration with Eli Lilly. Under our collaboration, Eli Lilly has an exclusive option to pursue clinical development of certain potential TCR product candidates. We and Eli Lilly have concluded the research phase of the collaboration and Eli Lilly is evaluating whether to exercise its option.'
Worth viewing their Vid too
meanwhile, their sp is doing a scancell lol
I think you might be confusing techs and platforms, easily done here with there being so much scientifically going on... Paston will be more involved with the BioNTech collab and TCRs than anything to do with the MaBs scancell brought in J Chua for her expertise on the MaBs (Avidimab) ...Paston does, however, appear now on one scientific poster around moditope and use of algorithms 'https://www.scancell.co.uk/Data/Sites/1/media/publications/posters/paris-2019-peptide-selection-final.pdf
Without a doubt a great addition to the team......Be interesting to see Immunocore IPO and market value attached to them ...another company I consider much less attractive than scancell but managed to raise £££'s from inestors and pharma
A company rarely mentioned here these days but back in the day was gone over in detail......
'OncoSec Announces $30 Million USD Strategic Investment at a Premium to Market by China Grand Pharmaceutical and Healthcare Holdings (CGP) in Connection with Exclusive License to TAVO™ in Greater China and 35 Other Asian Countries'
Well done them in pulling off something that will see their techs ( fat less appealing than scancells ) paid for to progress through clinics and at a premium to sp.... nice for their shareholders.... still no such joy here though
If we only get one shot at a moditope trial and at the moment it looks like that.. as no partner yet and it due to begin (in theory lol) in months it has to be done in a way that gives it the best possible chances of success ... the understanding of moditope and its mechanisms of action and who should best respond and what could go wrong is now higher than ever... It might well mean the dreaded... delay ... which we have all come to know too well here appears for that trial too but if that delay is about getting it completely right it will be worth it... we want and need moditope to be given the best chance of success possible
C7 well in the AGM recording in answering a question about BioNtech TCR she did mention they are also interested in vaccines ( took it to mean moditope vaccines) as are 'others'.... so probably talks going on there... and possibly a meeting with Lindy and Mellman in Paris... who knows!.... also we still await final plans for that trial as seems to be changing and the whole 'combo' part in light of the published papers one of which was about 'some patients have antigen specific T-regs that may
need to be neutralized'
I think that money is more for clinical work and costs of trials etc... the money that part of was to be used around doing deals with their TCR platform was raised right before they did the scancell tie up in 2018 ... about $270 million I think.... to me as ever I think it is mostly about the collab bearing fruit as in having a product at the end of it ready to go forward into the clinic that is when the deal would be done... they have the money already... and from sounds of it Lindy and Paston and co are well on to it despite being 6 months behind due to the now resolved HSE issue ... Also, the whole Lilly angle is interesting with them having a deal with BioNtech where they have been paying them a not too small amount to come up with a clinical TCR product since 2015... this year being the only year they did not pay them anything... hmmm
She left immunocore not adaptimmune however both companies share roots and she was there from those beginnings.....I do not rate either companies commercial futures myself however they have had loads of money which scancell has not been able to raise....if only eh
haha... I don't think Boom mean't it like that... he was going off the fact that SCIB1 failed to get a deal and a factor in that could well be pharma wanted more data... I think there will have been multiple factors main one being vaccine trial failure effect and then the target melanoma having many approved products ..... still now the battle is one of finding best combos think we are back in a better place with SCIB1.....
Anyways we know with TCR a preclinical deal is a very real possibility and the whole Lilly aspect of BioNTechs search for clinical TCRs I think is interesting and can't do any harm especially if 6 months down the line scancell come up with a clinically viable TCR product... Lilly have given BiNTech what scancell could call a fortune to come up with well ... nothing least nothing worth them paying them this year when they did the last few years...
'At the midpoint of the range, BioNTech would exit the IPO with $742 million in cash and equivalents. BioNTech has earmarked $100 million of the IPO haul for clinical development of three wholly owned off-the-shelf shared antigen immunotherapies and its share of the R&D budgets for candidates it is developing with Genentech, Sanofi and Genmab.
BioNTech has allocated $35 million to take CAR-Ts, T-cell receptors and mRNA-encoded antibodies and cytokines through phase 1 and set aside $20 million for preclinical work on other programs. Finally, BioNTech plans to use $15 million to add to its manufacturing and laboratory capacity.'
I noticed in BioNtechs pre IPO matterial... 2019 is the only year that Lilly who have a deal with them to come up with a clinical TCR product have not paid anything to BioNtech.... got to hurt BioNtech that... as looks like nothing is coming from that 2015 initiated deal.... yet is it possible Lindy will have within 6 months a clinically viable TCR product for BioNtech to take forwards? .... would BioNtech offer it up to Lilly so as to get more deal funds? what would Lilly think if scancell can do the job lol... hmm who knows lol but I guess it is a watch this space and an exciting arm to scancells multiple potentials
As with so much here we can only hope........ certainly seems a better chance now of getting something from pharma than a few years back.... I never discount that RNS arriving that both values and validates scancells approach
I thought p values were what is most important.... being able to get enough data to confidently know what results would be in a bigger cohort or in other words to know how effective a treatment will be out in the real world and so how commercially viable it is... The first SCIB1 trial gave quite a lot of such data... we know it is best as an Adjuvant treatment post resection we also know there is no point in running it in mono in late-stage non resected as the benefit will not be better than current CI's .... though it probably would be almost as good..... which when you look at values currently attached to CI's is quite something... If you got big money behind you you can do stuff... look at T Vec a product that is surely of lesser value than SCIB1 yet Amgen have managed to get it approved and it is not a commercial niche product... the clout of having funds that!
The next opportunity to improve #immunotherapy will come include appropriately primed T-cells. #Vaccine #ESMO19
It's one those subscription-only articles but guess from the title we get the gist.... and keeps RG earning his keep lol...
Think boom appertained scancell are not attending this particular ESMO